Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

Dimopoulos M. A., Sonneveld P., Rodriguez-Otero P., Quach H., Ho P. J., BEKSAÇ M., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Özet
  • Basım Tarihi: 2024
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Ankara Üniversitesi Adresli: Evet